We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it the Right Time to Add Phibro Stock to Your Portfolio?
Read MoreHide Full Article
Key Takeaways
Phibro's Animal Health sales rose 21%, led by MFA, nutritional specialty and vaccine growth.
PAHC is expanding vaccine capacity in Ireland and Israel to meet rising demand in key markets.
Higher input costs and foreign-exchange losses continue to weigh on Phibro's reported results.
Phibro Animal Health’s (PAHC - Free Report) Animal Health segment is gaining momentum from strong legacy demand, Zoetis medicated feed additives (MFA) acquisition and broad product growth. The vaccine business is expanding on higher demand, capacity investments and geographic growth. In addition, the company is seeing stronger demand for trace minerals, supporting growth in its Mineral Nutrition business. Meanwhile, Phibro faces macroeconomic, trade policy and foreign exchange risks that can increase costs and weigh on reported results.
In the past year, this Zacks Rank #1 (Strong Buy) stock has risen 1.6%, outpacing the industry’s 29.9% decline. The S&P 500 Composite has increased 18.1% over the same period.
The renowned animal health and mineral nutrition company has a market capitalization of $1.49 billion. PAHC has an earnings yield of 9.5% compared to the industry’s yield of 2.6%. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 18.4%.
Let’s delve deeper.
Tailwinds Supporting PAHC Stock
Animal Health Growth Broadens: Phibro’s Animal Health portfolio spans MFAs, vaccines and nutritional specialty products across major food animal species, giving the company several routes to support animal health and productivity. The Zoetis MFA acquisition materially broadened that portfolio, adding more than 37 product lines sold in approximately 80 countries. In fiscal 2026, Animal Health net sales increased 21% to $1.16 billion. MFAs and other products rose 25%, nutritional specialties increased 9% and vaccines grew 14%.
The acquired MFA portfolio contributed $358.2 million to fiscal 2026 sales, while legacy MFA demand increased in Mexico, Southeast Asia and the ethanol performance business. Management expects the acquired MFA portfolio to outpace overall company revenue growth in fiscal 2027, supported by momentum in North America and international growth opportunities.
Vaccine Franchise Keeps Expanding: Phibro continues to invest in vaccines as a differentiated growth platform within Animal Health. Fiscal 2026 vaccine net sales increased 14% to $156 million, driven by continued poultry growth in Latin America and higher domestic and international demand, particularly in Israel and Southeast Asia. Management is also increasing vaccine manufacturing capacity in Ireland and Israel to support demand, with related capital spending expected to rise in fiscal 2027 and 2028.
Image Source: Zacks Investment Research
The company’s broader Animal Health strategy combines vaccines with MFAs and nutritional specialties, giving commercial teams more tools for disease prevention, control and treatment. Management continues to identify vaccines as one of its primary internal and external business development priorities. This sustained investment, expanding manufacturing capacity and geographic demand provide a longer-term growth path that is less dependent on any single feed-additive product.
Mineral Nutrition Demand Recovers: Phibro’s Mineral Nutrition business provides another source of revenue diversity through trace mineral formulations used primarily in animal diets. Fiscal 2026 segment sales increased 11% to $282.3 million as demand rose for copper, zinc and trace minerals. Profit growth has been more modest because higher unit costs offset much of the volume benefit, with fiscal 2026 adjusted EBITDA increasing 4% to $21.7 million.
Even so, the higher sales base improves utilization and keeps the segment relevant as part of Phibro’s diversified portfolio. Management expects continued companywide growth in fiscal 2027, while Mineral Nutrition remains positioned to contribute when trace mineral demand is favorable.
What Ails Phibro?
Macroeconomic and Trade Policy Risks Remain: Phibro operates in markets exposed to sanctions, trade restrictions and military conflicts, like conflicts in the Middle East. Changes in U.S. trade policy, including new or increased tariffs and retaliatory measures, can disrupt supply chains and increase the cost of raw materials and other inputs.
Inflation in commodities, energy and distribution costs can also weigh on profitability when pricing actions do not fully offset higher costs. In fiscal 2026, higher input and distribution costs partly offset the benefits of increased sales, favorable product mix and higher average selling prices.
Foreign Exchange Exposure Adds Volatility: Phibro operates across multiple currencies, so exchange-rate movements can affect product costs, operating expenses and reported earnings. Foreign currency losses were $12.6 million in fiscal 2026 compared with $7.9 million in fiscal 2025. Management’s fiscal 2027 GAAP net income and earnings per share (EPS) framework assumes constant currency and no gains or losses from foreign-exchange movements. Actual currency swings therefore remain a source of variability around reported results.
PAHC Stock Estimate Trend
The Zacks Consensus Estimate for Phibro’s fiscal 2027 EPS has moved up 2% to $3.50 in the past 30 days.
The Zacks Consensus Estimate for the company’s fiscal 2027 revenues is pegged at $1.58 billion. This suggests a 3.4% rise from the year-ago reported number.
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 23.5% compared with the industry’s 3.9% growth. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Abbott, carrying a Zacks Rank #2 (Buy), has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT shares have plunged 26.5% compared with the industry’s 30.3% decline over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 22% compared with the industry’s 3.9% growth over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Is it the Right Time to Add Phibro Stock to Your Portfolio?
Key Takeaways
Phibro Animal Health’s (PAHC - Free Report) Animal Health segment is gaining momentum from strong legacy demand, Zoetis medicated feed additives (MFA) acquisition and broad product growth. The vaccine business is expanding on higher demand, capacity investments and geographic growth. In addition, the company is seeing stronger demand for trace minerals, supporting growth in its Mineral Nutrition business. Meanwhile, Phibro faces macroeconomic, trade policy and foreign exchange risks that can increase costs and weigh on reported results.
In the past year, this Zacks Rank #1 (Strong Buy) stock has risen 1.6%, outpacing the industry’s 29.9% decline. The S&P 500 Composite has increased 18.1% over the same period.
The renowned animal health and mineral nutrition company has a market capitalization of $1.49 billion. PAHC has an earnings yield of 9.5% compared to the industry’s yield of 2.6%. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 18.4%.
Let’s delve deeper.
Tailwinds Supporting PAHC Stock
Animal Health Growth Broadens: Phibro’s Animal Health portfolio spans MFAs, vaccines and nutritional specialty products across major food animal species, giving the company several routes to support animal health and productivity. The Zoetis MFA acquisition materially broadened that portfolio, adding more than 37 product lines sold in approximately 80 countries. In fiscal 2026, Animal Health net sales increased 21% to $1.16 billion. MFAs and other products rose 25%, nutritional specialties increased 9% and vaccines grew 14%.
The acquired MFA portfolio contributed $358.2 million to fiscal 2026 sales, while legacy MFA demand increased in Mexico, Southeast Asia and the ethanol performance business. Management expects the acquired MFA portfolio to outpace overall company revenue growth in fiscal 2027, supported by momentum in North America and international growth opportunities.
Vaccine Franchise Keeps Expanding: Phibro continues to invest in vaccines as a differentiated growth platform within Animal Health. Fiscal 2026 vaccine net sales increased 14% to $156 million, driven by continued poultry growth in Latin America and higher domestic and international demand, particularly in Israel and Southeast Asia. Management is also increasing vaccine manufacturing capacity in Ireland and Israel to support demand, with related capital spending expected to rise in fiscal 2027 and 2028.
Image Source: Zacks Investment Research
The company’s broader Animal Health strategy combines vaccines with MFAs and nutritional specialties, giving commercial teams more tools for disease prevention, control and treatment. Management continues to identify vaccines as one of its primary internal and external business development priorities. This sustained investment, expanding manufacturing capacity and geographic demand provide a longer-term growth path that is less dependent on any single feed-additive product.
Mineral Nutrition Demand Recovers: Phibro’s Mineral Nutrition business provides another source of revenue diversity through trace mineral formulations used primarily in animal diets. Fiscal 2026 segment sales increased 11% to $282.3 million as demand rose for copper, zinc and trace minerals. Profit growth has been more modest because higher unit costs offset much of the volume benefit, with fiscal 2026 adjusted EBITDA increasing 4% to $21.7 million.
Even so, the higher sales base improves utilization and keeps the segment relevant as part of Phibro’s diversified portfolio. Management expects continued companywide growth in fiscal 2027, while Mineral Nutrition remains positioned to contribute when trace mineral demand is favorable.
What Ails Phibro?
Macroeconomic and Trade Policy Risks Remain: Phibro operates in markets exposed to sanctions, trade restrictions and military conflicts, like conflicts in the Middle East. Changes in U.S. trade policy, including new or increased tariffs and retaliatory measures, can disrupt supply chains and increase the cost of raw materials and other inputs.
Inflation in commodities, energy and distribution costs can also weigh on profitability when pricing actions do not fully offset higher costs. In fiscal 2026, higher input and distribution costs partly offset the benefits of increased sales, favorable product mix and higher average selling prices.
Foreign Exchange Exposure Adds Volatility: Phibro operates across multiple currencies, so exchange-rate movements can affect product costs, operating expenses and reported earnings. Foreign currency losses were $12.6 million in fiscal 2026 compared with $7.9 million in fiscal 2025. Management’s fiscal 2027 GAAP net income and earnings per share (EPS) framework assumes constant currency and no gains or losses from foreign-exchange movements. Actual currency swings therefore remain a source of variability around reported results.
PAHC Stock Estimate Trend
The Zacks Consensus Estimate for Phibro’s fiscal 2027 EPS has moved up 2% to $3.50 in the past 30 days.
The Zacks Consensus Estimate for the company’s fiscal 2027 revenues is pegged at $1.58 billion. This suggests a 3.4% rise from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Abbott (ABT - Free Report) and Globus Medical (GMED - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 23.5% compared with the industry’s 3.9% growth. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott, carrying a Zacks Rank #2 (Buy), has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT shares have plunged 26.5% compared with the industry’s 30.3% decline over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 22% compared with the industry’s 3.9% growth over the past year.